Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

21 Dec 2022

Abstract excerpt

The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling pathway is dysregulated in nearly all kinds of neoplasms, with the component in this pathway alternations. RAF/MEK/ERK signaling cascades are used to conduct signaling from the cell surface to the nucleus to mediate gene expression, cell cycle processes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Melanoma and MAPK Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36539659
DOI: 10.1186/s43556-022-00110-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapyPMID 36539659Read ↗

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?Semantic proximity Read ↗

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Semantic proximity Read ↗

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Semantic proximity Read ↗

Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.Semantic proximity Read ↗

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerSemantic proximity Read ↗

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsSemantic proximity Read ↗

Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.Semantic proximity Read ↗

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Semantic proximity Read ↗

Current State and Future Challenges for PI3K Inhibitors in Cancer TherapySemantic proximity Read ↗

Targeting PI3K in cancer: mechanisms and advances in clinical trialsSemantic proximity Read ↗

Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin PathwaySemantic proximity Read ↗

AKT in cancer: new molecular insights and advances in drug developmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.